Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Empagliflozin with or without the Addition of Evolocumab on HDL Subspecies in Individuals with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EXCEED-BHS3 Trial.
Bonilha I, Gomes ÉIL, Carmo HRP, Breder I, Barreto J, Breder J, Munhoz DB, Carvalho LSF, Quinaglia T, Kimura-Medorima ST, Gossi CM, Zimetti F, Nadruz W, Zanotti I, Sposito AC; EXCEED-BHS3 Group. Bonilha I, et al. Among authors: zanotti i. Int J Mol Sci. 2024 Apr 8;25(7):4108. doi: 10.3390/ijms25074108. Int J Mol Sci. 2024. PMID: 38612917 Free PMC article.
Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial.
Breder I, Cunha Breder J, Bonilha I, Munhoz DB, Medorima STK, Oliveira DC, do Carmo HR, Moreira C, Kontush A, Zimetti F, Zanotti I, Carvalho LSF, Nadruz W, Muscelli E, Quinaglia T, Sposito AC; EXCEED-BHS3 Trial Investigator. Breder I, et al. Among authors: zanotti i. Ther Adv Chronic Dis. 2020 Sep 28;11:2040622320959248. doi: 10.1177/2040622320959248. eCollection 2020. Ther Adv Chronic Dis. 2020. PMID: 33062236 Free PMC article.
HDL-Targeted Therapies During Myocardial Infarction.
Sposito AC, Carmo HR, Barreto J, Sun L, Carvalho LSF, Feinstein SB, Zanotti I, Kontush A, Remaley A. Sposito AC, et al. Among authors: zanotti i. Cardiovasc Drugs Ther. 2019 Jun;33(3):371-381. doi: 10.1007/s10557-019-06865-1. Cardiovasc Drugs Ther. 2019. PMID: 30778806 Review.
Reciprocal Multifaceted Interaction Between HDL (High-Density Lipoprotein) and Myocardial Infarction.
Sposito AC, de Lima-Junior JC, Moura FA, Barreto J, Bonilha I, Santana M, Virginio VW, Sun L, Carvalho LSF, Soares AAS, Nadruz W, Feinstein SB, Nofer JR, Zanotti I, Kontush A, Remaley AT. Sposito AC, et al. Among authors: zanotti i. Arterioscler Thromb Vasc Biol. 2019 Aug;39(8):1550-1564. doi: 10.1161/ATVBAHA.119.312880. Epub 2019 Jun 13. Arterioscler Thromb Vasc Biol. 2019. PMID: 31189429 Free article. Review.
Lipid trafficking in cardiovascular disease.
Sposito AC, Zimetti F, Barreto J, Zanotti I. Sposito AC, et al. Among authors: zanotti i. Adv Clin Chem. 2019;92:105-140. doi: 10.1016/bs.acc.2019.04.002. Epub 2019 May 29. Adv Clin Chem. 2019. PMID: 31472752 Review.
Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity.
de Lima-Junior JC, Virginio VWM, Moura FA, Bertolami A, Bertolami M, Coelho-Filho OR, Zanotti I, Nadruz W, de Faria EC, de Carvalho LSF, Sposito AC. de Lima-Junior JC, et al. Among authors: zanotti i. Nutr Metab Cardiovasc Dis. 2020 Feb 10;30(2):254-264. doi: 10.1016/j.numecd.2019.09.017. Epub 2019 Sep 23. Nutr Metab Cardiovasc Dis. 2020. PMID: 31753789
58 results